Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand?
- PMID: 39025099
- DOI: 10.1016/S2468-1253(24)00186-9
Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand?
Erratum in
-
Correction to Lancet Gastroenterol Hepatol 2024; 9: 774-75.Lancet Gastroenterol Hepatol. 2025 Jan;10(1):e1. doi: 10.1016/S2468-1253(24)00400-X. Lancet Gastroenterol Hepatol. 2025. PMID: 39674231 No abstract available.
Conflict of interest statement
SDH has received consulting fees from Takeda and is a recipient of research funding from Crohn's and Colitis Foundation, and the American Society of Colon and Rectal Surgeons. BC received consulting fees from AbbVie, Prometheus, and TARGET-RWE; advisory board fees from AbbVie, Bristol Meyers Squibb, Janssen, Pfizer, and Takeda; and honoraria from ALPCO, Cornerstones Health, and Monday Night IBD.
Comment on
-
Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial.Lancet Gastroenterol Hepatol. 2024 Sep;9(9):793-801. doi: 10.1016/S2468-1253(24)00097-9. Epub 2024 Jul 15. Lancet Gastroenterol Hepatol. 2024. PMID: 39025100 Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
